Development of clinical decision support alerts for pharmacogenomic incidental findings from exome sequencing

被引:20
|
作者
Nishimura, Adam A. [1 ]
Shirts, Brian H. [2 ]
Dorschner, Michael O. [2 ,3 ,4 ]
Amendola, Laura M. [5 ]
Smith, Joe W. [6 ]
Jarvik, Gail P. [3 ,5 ]
Tarczy-Hornoch, Peter [1 ,7 ,8 ]
机构
[1] Univ Washington, Dept Biomed Informat & Med Educ, Seattle, WA 98195 USA
[2] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[3] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA
[4] Univ Washington, Dept Pathol, Seattle, WA 98195 USA
[5] Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA
[6] Univ Washington, Sch Pharm, Seattle, WA 98195 USA
[7] Univ Washington, Dept Pediat, Seattle, WA 98195 USA
[8] Univ Washington, Dept Comp Sci & Engn, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
clinical decision support; clinical informatics; electronic medical records; genomic medicine; pharmacogenomics; RANDOMIZED-TRIAL; IMPLEMENTATION; MEDICINE; RECOMMENDATIONS; UNIVERSITY; DESIGN;
D O I
10.1038/gim.2015.5
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose: Electronic health records (EHRs) and their associated decision support tools are potentially important means of disseminating a patient's pharmacogenomic profile to his or her health-care providers. We sought to create a proof-of-concept decision support alert system generated from pharmacogenomic incidental findings from exome sequencing. Methods: A pipeline for alerts from exome sequencing tests was created for patients in the New EXome Technology in (NEXT) Medicine study at the University of Washington. Decision support rules using discrete, machine-readable incidental finding results were programmed into a commercial EHR rules engine. An evaluation plan to monitor the alerts in real medical interactions was established. Results: Alerts were created for 48 actionable pharmacogenomic variants in 11 genes and were launched on 24 September 2014 for-University of Washington inpatient care. Of the 94 participants enrolled in the NEXT Medicine study, 49 had one or more pharmacogenomic variants identified for return. Conclusion: Reflections on the process reveal that while incidental findings can be used to generate decision support alerts, substantial resources are required to ensure that each alert is consistent with rapidly evolving pharmacogenomic literature and is customized to fit in the clinical workflow unique to each incidental finding.
引用
收藏
页码:939 / 942
页数:4
相关论文
共 50 条
  • [21] Exploring concordance and discordance for return of incidental findings from clinical sequencing
    Green, Robert C.
    Berg, Jonathan S.
    Berry, Gerard T.
    Biesecker, Leslie G.
    Dimmock, David P.
    Evans, James P.
    Grody, Wayne W.
    Hegde, Madhuri R.
    Kalia, Sarah
    Korf, Bruce R.
    Krantz, Ian
    McGuire, Amy L.
    Miller, David T.
    Murray, Michael F.
    Nussbaum, Robert L.
    Plon, Sharon E.
    Rehm, Heidi L.
    Jacob, Howard J.
    GENETICS IN MEDICINE, 2012, 14 (04) : 405 - 410
  • [22] Incidental findings from clinical sequencing in Greece: reporting experts’ attitudes
    Gourna E.G.
    Armstrong N.
    Wallace S.E.
    Journal of Community Genetics, 2014, 5 (4) : 383 - 393
  • [23] Who's on first in exome and whole genome sequencing? Is it the patient or the incidental findings?
    Rosenblatt, David S.
    MOLECULAR GENETICS AND METABOLISM, 2013, 110 (1-2) : 1 - 2
  • [24] ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing (vol 15, pg 565, 2013)
    Green, Robert C.
    Berg, Jonathan S.
    Grody, Wayne W.
    Kalia, Sarah S.
    Korf, Bruce R.
    Martin, Christa L.
    McGuire, Amy L.
    Nussbaum, Robert L.
    O'Daniel, Julianne M.
    Ormond, Kelly E.
    Rehm, Heidi L.
    Watson, Michael S.
    Williams, Marc S.
    Biesecker, Leslie G.
    GENETICS IN MEDICINE, 2017, 19 (05) : 606 - 606
  • [25] LABORATORY POLICIES ON REPORTING INCIDENTAL FINDINGS IN CLINICAL WHOLE EXOME AND GENOME SEQUENCING: UPTAKE OF THE 2013 ACMG RECOMMENDATIONS
    Hufnagel, Sophia B.
    Antommaria, Andarmand H. Matheny
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2015, 167 (08) : 1703 - 1704
  • [26] Implementing Pharmacogenomic Clinical Decision Support into German Hospitals
    Hinderer, Marc
    Boerries, Melanie
    Boeker, Martin
    Neumaier, Michael
    Loubal, Frank-Peter
    Acker, Till
    Brunner, Manfred
    Prokosch, Hans-Ulrich
    Christoph, Jan
    BUILDING CONTINENTS OF KNOWLEDGE IN OCEANS OF DATA: THE FUTURE OF CO-CREATED EHEALTH, 2018, 247 : 870 - 874
  • [27] Frequency of Medically Actionable Incidental Findings from Exome Sequencing Data of Deemed Healthy Individuals from India
    Bhanushali, Aparna
    Kulkarni, Smita
    Shah, Sanchi
    Prabha, Anu
    Pradhan, Ashlesha
    Chatterjee, Anirvan
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2024, 26 (06): : S1 - S2
  • [28] Clinician Response to Pharmacogenetic Clinical Decision Support Alerts
    Lemke, Lauren K.
    Cicali, Emily J.
    Williams, Roy
    Nguyen, Khoa A.
    Cavallari, Larisa H.
    Wiisanen, Kristin
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (06) : 1350 - 1357
  • [29] CHARACTERISTICS OF PROVIDERS WHO RESPONDED TO PASSIVE CLINICAL DECISION SUPPORT ALERTS FOLLOWING PRE-EMPTIVE RETURN OF PHARMACOGENOMIC RESULTS
    Martin, J.
    Shalowitz, E.
    Kao, D.
    Trinkley, K.
    Aquilante, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S89 - S89
  • [30] Frequency and management of medically actionable incidental findings from genome and exome sequencing data: a systematic review
    Elfatih, Amal
    Mohammed, Idris
    Abdelrahman, Doua
    Mifsud, Borbala
    PHYSIOLOGICAL GENOMICS, 2021, 53 (09) : 373 - 384